MERRIMACK PHARMACEUTICALS IN's ticker is MACKXXXX and the CUSIP is 590328100. A total of 138 filers reported holding MERRIMACK PHARMACEUTICALS IN in Q4 2016. The put-call ratio across all filers is 2.24 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $1,144,000 | -41.3% | 280,279 | -8.7% | 0.00% | -50.0% |
| Q3 2016 | $1,949,000 | +236.6% | 306,854 | +185.6% | 0.00% | +100.0% |
| Q2 2016 | $579,000 | -38.7% | 107,436 | -4.7% | 0.00% | 0.0% |
| Q1 2016 | $944,000 | -50.9% | 112,703 | -53.7% | 0.00% | -50.0% |
| Q4 2015 | $1,924,000 | +1.6% | 243,541 | +9.5% | 0.00% | 0.0% |
| Q3 2015 | $1,893,000 | -33.3% | 222,465 | -3.1% | 0.00% | -33.3% |
| Q2 2015 | $2,838,000 | -29.0% | 229,531 | -31.8% | 0.00% | -25.0% |
| Q1 2015 | $3,998,000 | +2.9% | 336,509 | -2.1% | 0.00% | 0.0% |
| Q4 2014 | $3,886,000 | +119.3% | 343,878 | +70.3% | 0.00% | +100.0% |
| Q3 2014 | $1,772,000 | +482.9% | 201,868 | +384.8% | 0.00% | – |
| Q2 2014 | $304,000 | +19.2% | 41,636 | -17.7% | 0.00% | – |
| Q1 2014 | $255,000 | -0.8% | 50,565 | +5.0% | 0.00% | – |
| Q4 2013 | $257,000 | +53.0% | 48,143 | +8.7% | 0.00% | – |
| Q3 2013 | $168,000 | -41.1% | 44,310 | +4.7% | 0.00% | – |
| Q2 2013 | $285,000 | – | 42,314 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lagoda Investment Management, L.P. | 2,100,140 | $25,968,000 | 6.81% |
| Portolan Capital Management | 664,298 | $8,214,000 | 1.15% |
| GARRISON BRADFORD & ASSOCIATES INC | 90,700 | $1,122,000 | 1.10% |
| Opus Point Partners Management, LLC | 72,009 | $890,000 | 0.70% |
| Eagle Ridge Investment Management | 122,500 | $1,515,000 | 0.68% |
| EAM Investors, LLC | 350,410 | $4,333,000 | 0.51% |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 4,881,667 | $60,362,000 | 0.37% |
| Cannell & Co. | 1,051,178 | $12,998,000 | 0.37% |
| Birchview Capital, LP | 42,300 | $523,000 | 0.28% |
| Tekla Capital Management LLC | 567,787 | $7,021,000 | 0.25% |